How Investors Are Reacting To Incyte (INCY) EMA Boost For Zynyz In First-Line Anal Cancer [Yahoo! Finance]
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: Yahoo! Finance
chemotherapy as first-line treatment for adults with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal, based on Phase 3 data showing improved progression-free survival and no new safety signals. This marks a potential expansion of Incyte's immuno-oncology footprint in Europe in a rare cancer where treatment options remain limited despite accounting for most anal cancer cases. We'll now examine how this positive CHMP opinion for Zynyz in first-line anal cancer may influence Incyte's broader investment narrative. These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs . Discover why before your portfolio feels the trade war pinch. To own Incyte, you need to be comfortable with a story that leans on a profitable base business while trying to broaden its oncology footprint. Jakafi and Opzelura still look like the key short term drivers, with upcoming Q4 2025 results and any 2026 guidance twea
Show less
Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- Incyte (INCY) Q4 Earnings: What To Expect [Yahoo! Finance]Yahoo! Finance
- Incyte (NASDAQ:INCY) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
- TD Cowen Keeps Buy Rating on Incyte (INCY), Cites Roadmap to Triple Non-Jakafi Revenue by 2029 [Yahoo! Finance]Yahoo! Finance
- Incyte (NASDAQ:INCY) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $135.00 price target on the stock.MarketBeat
- Analysts Differ in Opinion on Jakafi Drug Maker Incyte (INCY) [Yahoo! Finance]Yahoo! Finance
INCY
Earnings
- 10/28/25 - Beat
INCY
Sec Filings
- 2/4/26 - Form 4
- 2/4/26 - Form 4
- 1/21/26 - Form 4
- INCY's page on the SEC website